Vensana Capital, a Minneapolis-based venture capital firm specializing in medtech investments, has successfully closed its third fund, raising $425 million. This latest fundraising effort brings Vensana's total capital under management to approximately $1 billion.

1. Oversubscribed at its hard cap, indicating strong investor interest

2. Focuses on medtech companies at both developmental and commercial stages

3. Typically invests $30 million to $35 million per company

4. Aims to support startups creating new clinical standards of care and improving healthcare efficiency, accessibility, and cost-effectiveness

Vensana's investment strategy has proven successful, as evidenced by:

- The acquisition of portfolio company Relievant Medsystems by Boston Scientific for $850 million in 2023

- 20% of their investments historically being in Twin Cities-based companies

- Supporting companies like CVRx, which has gone public and commercialized an implant for heart failure patients

Kirk Nielsen, co-founder and Managing Partner, attributes the efficient fundraising process to investor support and satisfaction with the firm's strategy. He also notes that access to capital remains a challenge for many startups in 2025, highlighting the continued importance of venture capital in the medtech sector.

----

Join the Future of Venture Capital Investing with Newnex

Newnex is the platform focused on institutional investors where verified startups, VCs, and LPs converge for private fundraising and investment through trusted references. Centralize your fundraising and investment activities and access the global VC network with just a few clicks. Join for free at www.newnex.io

We are digitalizing institutional investing to make VC as accessible as public markets while retaining the uniqueness of private markets. The mission is to unify 5,000+ VC/LP firms with 100,000 startups on a trusted platform for reference-only private deal-making.

---

Disclaimer: The information presented in this article is based on available sources and may not be entirely accurate or up-to-date. We do not guarantee the accuracy of the content, and readers should conduct their own research and consult with financial professionals before making any decisions.